Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.…
GENIL’den 5 milyar TL’lik satın alma: Yeni sektör enerji oldu
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST: GENIL) is listed on Borsa Istanbul, where its shares trade in TRY. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 690 employees.
The shares were at 4.250 TRY on 20 November 2026, down 65.3% over 52 weeks. Its 52-week range is 3.160 TRY to 13.31 TRY: the price is 68.1% below the high and 34.5% above the low.
At a market capitalisation of 19.11B TRY, it trades at 17.7 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a discount of 28% for GENIL. It pays a dividend yielding 0.58% (it pays out 13% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi reports return on equity of 7.9%, an operating margin of 13.4% and revenue down 17.8% year over year.
Its debt exceeds its cash by 4.98B TRY, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.
No upcoming events tracked.